Prime Medicine, Inc. Increase (Decrease) in Contract with Customer, Liability
Prime Medicine, Inc. (PRME) reported Increase (Decrease) in Contract with Customer, Liability of -$1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$1.13M.
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$856.00K.
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$751.00K.
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$1.18M, a 101.63% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$4.36M, a 106.20% decline from fiscal 2024.
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $70.31M.
- Prime Medicine, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.98M 10-Q · filed 2026-08-06 | -$2.73M derived: sum of 3 quarters · filed 2026-08-06 | -$3.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$856.00K 10-Q · filed 2026-05-07 | -$1.61M derived: sum of 2 quarters · filed 2026-05-07 | -$2.78M derived: sum of 3 quarters · filed 2026-05-07 | -$3.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$751.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.93M derived: sum of 2 quarters · filed 2026-03-03 | -$2.92M derived: sum of 3 quarters · filed 2026-08-06 | -$4.36M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$2.17M derived: sum of 2 quarters · filed 2026-08-06 | -$3.61M 10-Q · filed 2025-11-07 | -$5.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$995.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.43M 10-Q · filed 2026-08-06 | -$4.04M derived: sum of 3 quarters · filed 2026-08-06 | $67.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.44M 10-Q · filed 2026-05-07 | -$3.05M derived: sum of 2 quarters · filed 2026-05-07 | $68.87M derived: sum of 3 quarters · filed 2026-05-07 | $68.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $70.31M derived: sum of 2 quarters · filed 2026-03-03 | $70.31M derived: sum of 3 quarters · filed 2026-03-03 | $70.31M 10-K · filed 2026-03-03 |
| 2024-09-30 | $71.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $71.92M derived: sum of 2 quarters · filed 2025-11-07 | $71.92M 10-Q · filed 2025-11-07 | $71.92M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |